#Italy #Newronika #Advent #Monza #αDBS

Newronika's Breakthrough in Parkinson's Disease Treatment

In a significant development for the realm of neurological health, Newronika S.p.A., a pioneering medical technology company, has announced the successful implantation of the first participant in their pivotal ADVENT study. This milestone not only marks a leap forward in research related to Parkinson's disease but also emphasizes Newronika's commitment to advancing adaptive deep brain stimulation therapies.

A New Era for Parkinson's Treatment

The implantation procedure was performed on September 21, 2026, at the esteemed Hospital Fondazione IRCCS San Gerardo dei Tintori, based in Monza, Italy. The ADVENT study aims to evaluate the effectiveness of Newronika's αDBS® adaptive deep brain stimulation system against conventional stimulation methods for patients suffering from Parkinson's disease. This pivotal study is expected to provide crucial insights into how adaptive therapies can enhance treatment outcomes for individuals who have not found relief through typical medication.

Lorenzo Rossi, Co-Founder and CEO of Newronika, stressed the importance of this step in the clinical development of adaptive deep brain stimulation. According to Rossi, the study's design is rigorous and will generate essential evidence comparing both stimulation strategies within the same group of participants. This comparative approach aims to elevate the standards of care for those diagnosed with this progressive neurological disorder.

Understanding the ADVENT Study

The ADVENT study, officially registered as NCT06891781 on ClinicalTrials.gov, is a multicenter, randomized, double-blind crossover investigation that encompasses safety and efficacy assessments of adaptive versus conventional deep brain stimulation. The study will enroll approximately 104 adults diagnosed with idiopathic Parkinson's disease, who have been recommended for bilateral deep brain stimulation targeting the subthalamic nucleus. Up to 18 specialized clinical sites across both the United States and the European Union are anticipated to participate in this groundbreaking research.

What sets the ADVENT study apart is its crossover design, allowing each participant to experience both forms of stimulation in a randomly assigned order. This dual experience is crucial for obtaining unbiased data regarding the effectiveness of each approach. The secrecy surrounding the active mode of stimulation for both participants and their clinicians during the study is an innovative method to ensure the integrity of the findings.

Newronika has received FDA approval for an Investigational Device Exemption, which is pivotal for initiating the ADVENT pivotal study. The findings from this research are projected to support a future Premarket Approval application for Newronika's advanced deep brain stimulation system in the United States, should the results prove favorable.

Parkinson's Disease and Treatment Methods

Currently, Parkinson's disease is a progressive neurological condition that presents a range of debilitating symptoms, including tremors, stiffness, and slowed movement. While traditional deep brain stimulation (DBS) has been established as a viable treatment option for suitable candidates, it has its limitations. Conventional DBS typically employs fixed stimulation settings determined by clinicians, which remain unchanged until adjustments are warranted. In contrast, Newronika's adaptive DBS is designed to dynamically respond to real-time brain activity, augmenting stimulation levels based on established clinical guidelines.

About Newronika

Founded in Milan and emerging from two foremost Italian research institutions, Newronika has dedicated over 20 years to developing advanced medical technologies. The αDBS® technology exemplifies their innovative approach as it continuously monitors and adapts to neurophysiological conditions, providing a personalized therapeutic experience for patients. As Newronika ventures into this landmark study, the company's motto emphasizes its pioneering spirit: “Parkinson's disease is where we start. The brain is where we're going.”

For additional insights about Newronika and their ongoing research initiatives, including details about the ADVENT study, visit their official website at www.newronika.com.

In conclusion, the progress made by Newronika in the ADVENT study presents a promising avenue for enhancing the quality of life for individuals grappling with Parkinson's disease, paving the way for further innovations in neurotechnological therapies.